MEDICAL POLICY

SUBJECT: VARICOSITIES, TREATMENT ALTERNATIVES TO VEIN STRIPPING AND LIGATION

POLICY NUMBER: 7.01.47
CATEGORY: Technology Assessment

EFFECTIVE DATE: 10/18/01
REVISED DATE: 04/17/02, 04/21/05, 04/20/06, 04/19/07, 03/20/08, 09/17/09, 10/28/10, 05/19/11, 05/24/12, 06/20/13, 05/22/14, 06/18/15, 07/21/16

PAGE: 1 OF 9

• If the member’s subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
• Medical policies apply to commercial and Safety Net products only when a contract benefit for the specific service exists.

***Note: This policy does not address vein stripping and ligation. Please refer to the nationally recognized InterQual standards regarding vein stripping and ligation. ***

POLICY STATEMENT:

I. Based on our criteria and review of peer-reviewed literature, treatment of documented symptomatic* varicose veins with reflux is considered medically appropriate when treated with the following techniques and when the patient has failed a course of conservative therapy:
   A. Ambulatory phlebectomy, transilluminated powered phlebectomy (TPP/TIPP, TriVex) and stab phlebectomy;
   B. Endoluminal radiofrequency ablation (e.g., VNUS® ClosureFAST™, ClosurePlus™);
   C. Laser ablation of the saphenous vein, including endovenous laser ablation (EVLA) of the saphenous vein (ELAS) or endovenous laser treatment (EVLT); or
   D. Compressive sclerotherapy (liquid or foam, including microfoam [e.g. Varithena™]) as an adjunct to prior or concomitant surgical treatment of venous reflux disease.

*A patient is considered to have symptomatic varicose veins if any of the following signs and symptoms of significantly diseased vessels of the lower extremities are documented:
   A. stasis ulcer of the lower leg, or
   B. significant symptoms (e.g., pain, heaviness) that are refractory to a 12 week course of conservative therapy (e.g., utilization of compressive hose, systematic anti-inflammatories/analgesics, or activity modification), or
   C. bleeding associated with the diseased vessels of the lower extremities, or
   D. recurrent episodes of superficial phlebitis, or
   E. stasis dermatitis.

II. Based on our criteria and review of peer-reviewed literature, the following are considered not medically necessary:
   A. Compressive sclerotherapy when performed for dermal or subdermal cosmetic lesions, for star and/or flare lesions, spider nevi, and/or telangiectasia;
   B. Microsclerosis (injection of telangiectasia or spider veins);
   C. Non-compressive sclerotherapy; or
   D. Transcutaneous laser ablation of telangiectasia.

III. Based upon our criteria and review of the peer-reviewed literature, the following are considered investigational as the treatments have not been medically proven to be effective:
   A. Endovascular embolization with a cyanoacrylate adhesive (e.g., VenaSeal™ Closure System);
   B. Intense pulsed light source (photothermal sclerosis) in the treatment of superficial veins;
   C. Mechanochemical endovenous ablation (MOCA) (e.g., ClariVein®);
   D. Sclerotherapy as the sole treatment of varicose tributaries with documented reflux of the saphenofemoral junction or reflux isolated to the perforator veins of the upper thigh;
   E. Sclerotherapy of the greater saphenous vein with or without associated ligation of the saphenofemoral junction;
   F. Transcutaneous laser ablation of small diameter veins.

Proprietary Information of YourCare Health Plan
POLICY GUIDELINES:

I. Treatment of some varicose veins may be considered cosmetic in nature. Treatment of varicose veins for cosmetic purposes is **not medically necessary**.

II. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

The venous system of the lower extremities consists of the **superficial** system (greater and lesser saphenous veins) and the **deep** system (popliteal and femoral veins). These two parallel systems are interconnected via **perforator** veins. One-way valves are present at the junctions between the bifurcation point of the deep and superficial system (e.g., saphenofemoral and the saphenopopliteal junction).

Varicose veins of the superficial system are typically secondary to valve incompetence. While most are secondary to incompetent valves at the saphenofemoral or saphenopopliteal junctions, a minority may be secondary to incompetence of valves within the perforator veins. Varicose veins may be asymptomatic or symptomatic. Although many varicose veins are asymptomatic, when they are present symptoms include itching, heaviness, aching legs, tension, and pain. In addition, varicose veins may be complicated by peripheral edema due to venous insufficiency, hemorrhage, thrombophlebitis, venous ulceration, and chronic skin changes. Larger varicose veins may be tortuous protruding above the surface of the skin.

Treatment options typically first on identifying and correcting the site of reflux, and second to redirecting venous flow through veins with intact valves. Thus surgical treatment of varicosities associated with valve incompetence is based on the following three principles:

I. Control of the most proximal point of reflux, typically at the saphenofemoral junction, as identified by preoperative Doppler ultrasonography. Surgical ligation is the most common form of treatment of the site of reflux.

II. Isolation of the refluxing greater saphenous from the circulation. The most typical strategy for isolation is vein stripping, which is always preceded by ligation.

III. Removal of the varicose tributaries. Strategies for this removal may include procedures such as stab avulsion or injection sclerotherapy, either at the time of the initial treatment, or subsequently.

Over the years various different minimally invasive alternatives to ligation and stripping have been investigated. For example, sclerotherapy of the saphenous vein (as opposed to sclerotherapy of the varicose tributaries) is designed to promote fibrosis of the saphenous vein and thus remove it from the circulation.

The term “varicose veins” does not apply to telangiectatic dermal veins, which may be described as spider veins or broken blood vessels. While abnormal in appearance, these veins typically are not associated with any symptoms (such as pain or heaviness) and their treatment is typically considered cosmetic in nature.

Ambulatory phlebectomy

*Ambulatory phlebectomy* (also known as microphlebectomy or microincisional phlebectomy) is the removal of varicose veins through a series of tiny incisions along the path of an enlarged vein. Prior to surgery the degree of reflux in incompetent veins is evaluated and the location of the veins is determined by Doppler ultrasound. The vessels are marked with a surgical marker. The surgical procedure is done under local tumescent anesthesia. Small pinhole incisions are made adjacent to the varicose veins. A small stripper head is inserted, turns the vein inside out and peels it away from the soft tissues of the leg through a minimal skin opening. Afterward the leg is wrapped with a compression bandage.

*Stab phlebectomy* is a type of ambulatory phlebectomy also known as the “crochet hook” method of stab avulsion.

*Transilluminated powered phlebectomy (TPP/TIPP)*, also known as the *TriVex procedure*, is a minimally invasive type of ambulatory phlebectomy offered as an alternative to standard surgery for symptomatic varicosities of the leg. It is a 3-part procedure performed under general, regional, or local anesthesia, beginning with tumescent anesthesia to enhance...
visualisation surrounding the varicose veins and to reduce operative discomfort. Tumescent anaesthesia involves infusion of large amounts of saline mixed with lidocaine to reduce hemorrhage and epinephrine to delay absorption of lidocaine. Once adequate tumescent infiltration is achieved, the resector and illuminator are inserted and positioned underneath the skin through small (2-3 cm) incisions on either end of the varicosity. The tip of the resector follows the veins slowly to chop the veins an aspirate fragments. Once removal of the affected vein(s) is complete, a second stage tumescent anesthesia is employed to minimize blood loss, to reduce bruising and hematoma formation, and to decrease post-operative pain. The incisions are then closed using surgical tape or similar closures, and the leg is wrapped.

Endoluminal Radiofrequency Ablation of Varicose Veins (VNUS®)

Endoluminal radiofrequency ablation is a minimally invasive alternative to vein ligation and stripping. The technique relies on radiofrequency energy to damage the intimal wall of the vessel resulting in fibrosis and ultimately obliteration of a long segment of the vein, thus eliminating reflux. The procedure is performed by means of a specifically designed catheter (VNUS® ClosureFAST™ catheter, VNUS Technologies) inserted through a small incision in the distal medial thigh to within 1-2 cm. of the sapheno-femoral junction. High frequency radio waves (200-300 kHz) are delivered through the catheter electrode and cause direct heating of the adjacent tissues. The vein is heated to approximately 120°C for 20-second intervals to sequentially heat and ablate the vein in seven cm increments.

Intense Pulsed Light Source

Intense pulsed light source or photothermal sclerosis (such as PhotoDerm® Vasculite™). The light source is not a laser and involves no needles or incisions. Treatment consists of small pulses of light energy traveling through the skin, which is absorbed by the blood, changed to heat, and the vein is destroyed. It is used for smaller surface veins.

LASER (Light Amplification by the Stimulated Emission of Radiation) Ablation

Laser ablation of symptomatic varicose veins, such as but not limited to endovenous laser ablation (EVLA) of the saphenous vein (ELAS) or endovenous laser treatment (EVLT), consists of a bare-tipped or ceramic coated tip laser fiber being introduced through a small incision into the greater saphenous vein under ultrasound guidance. The laser is activated, with the resulting heat at the tip causing a reaction in the walls of the vein, and then being slowly removed along the course of the saphenous vein. Damage to the intimal wall of the vessel results in fibrosis and ultimately obliteration of a long segment of the vein. The varicosities associated with this vein then disappear and blood from the lower leg reroutes through deeper circulation.

Transcutaneous laser ablation of small diameter veins. A small spot of laser travels through the skin and is absorbed by the blood within the vein. The resulting heat coagulates the blood and destroys the function of the vein. Over time the vein will be absorbed by the body and will disappear from sight.

Laser Ablation of Telangiectasias (spider veins). Telangiectasia is a vascular lesion formed by dilation of a group of small blood vessels. Telangiectasia may appear as birthmarks or become apparent in young children. Acquired telangiectasia may also be caused by long-term sun exposure. Although the lesions may occur anywhere on the skin, they are seen most frequently on the face and thighs. Hereditary hemorrhagic telangiectasia is a disease transmitted by autosomal dominant inheritance marked by thinness of the walls of the blood vessels of the nose, skin, and digestive tract as well as a tendency to hemorrhage. Rendu-Osler Weber syndrome is a form of hereditary hemorrhagic telangiectasia.

Mechanochemical endovenous ablation (MOCA)

Mechanochemical endovenous ablation utilizes both sclerotherapy and mechanical damage to the lumen. Following ultrasound imaging, a disposable catheter with a motor drive is inserted into the distal end of the target vein and advanced to the saphenofemoral junction. As the catheter is pulled back, a wire rotates within the lumen of the vein, abrading the lumen. At the same time, a liquid sclerosant (sodium tetradecyl sulphate) is infused near the rotating wire. It is proposed that mechanical ablation allows for better efficacy of the sclerosant, without the need for the tumescent anesthesia used in radiofrequency ablation or endovenous laser ablation. The ClariVein® Infusion Catheter is utilized to perform MOCA and received 510(k) approval by the U.S. Food and Drug Administration (FDA) in February 2008. The system includes an infusion catheter, motor drive, stopcock and syringe and is intended for the infusion of physician-specified agents in the peripheral vasculature. Although there are no formal contraindications to use ClariVein besides allergy to the
sclerosant, many studies have excluded patients on anticoagulants and those with a history of deep vein thrombosis (DVT) or limb infection.

Sclerotherapy (Sclerosing Injection/Compression Therapy)

*Sclerotherapy* is a method of eliminating cutaneous varicose veins in which a sclerosing agent is injected into the veins. The principle of sclerotherapy is to cause irreversible endothelial injury in the desired location, while avoiding any damage to normal vessels that may be interconnected with the abnormal vessel being treated. Sclerotherapy usually requires no anesthesia and is performed in the outpatient setting or in the practitioner’s office setting. It is sometimes performed in situations that might otherwise require surgery. Since the saphenous vein is not visible with the naked eye, injection may be guided by ultrasonography, and the combined procedure may be referred to as *echosclerotherapy*.

Technical improvements in sclerotherapy have included the routine use of Duplex ultrasound to target refluxing vessels, luminal compression of the vein with anesthetics, and a foam/sclerosant injectate in place of liquid sclerosant. Foam sclerosants are produced by forcibly mixing a gas (e.g., air or carbon dioxide) with a liquid sclerosant (e.g., polidocanol or sodium tetradecyl sulfate). In November 2013, the FDA approved Varithena™, a foam sclerosant that utilizes micro bubbles (microfoam) and is composed of polidocanol. Varithena™ is dispersed from a canister with a controlled density and a more consistent bubble size. Varithena™ is used for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee. Varithena is contraindicated in patients who are allergic to acute thromboembolic disease or polidocanol. Varithena should not be used in nursing or pregnant women and pediatric patients. Patients with underlying arterial disease may have increased risk for tissue ischemia. There is also an increased risk for thrombosis in patients who have had a recent major surgery, reduced mobility, history of pulmonary embolism (PE) or DVT, pregnancy, or prolonged hospitalization.

*Compressive sclerotherapy* involves injection of the sclerosant into an “empty” vein (elevated limb) followed by application of compressive dressings. This is the most commonly performed sclerotherapy procedure for varicose veins of the lower extremities.

*Non-compressive sclerotherapy* implies injection of the sclerosant into veins when the patient is upright and the veins are “full”. Technically this is thrombotic therapy, not sclerotherapy.

Percutaneous techniques, specifically US-guided sclerotherapies are recommended over open venous perforator vein surgery in patients with venous leg ulcers according to the Society for Vascular Surgery (SVS) and American Venous Forum (AVF).

**Other treatments**

On Feb 20, 2015, the FDA granted pre-market approval of the VenaSeal Closure System to treat superficial varicosities of the legs through *endovascular embolization* and is intended for adults with clinically symptomatic venous reflux diagnosed by duplex ultrasound. The VenaSeal system is a tumescentless technique that utilizes a cyanoacrylate-based adhesive that is injected into a diseased vein via a catheter inserted through the skin, while being monitored by ultrasound. Once the adhesive is injected the area is manually compressed and the adhesive changes into a solid to seal the varicose vein.

Other proposed methods of treating varicose veins include steam injection (Steam Vein Sclerosis System [SVSTM, VenoSteam™], CermaVEIN, France) and endovenous microwave ablation (Microwave Intracavitary Coagulation System, Shanghai Medical Electronics, China). Results of a small, preliminary study performed outside of the U.S., for each system, have been reported. Neither of these procedures have been approved or cleared for marketing by U.S. Food and Drug Administration (FDA). A search of the FDA website did not identify any information regarding either system.

**RATIONALE:**

Ambulatory phlebectomy, including but not limited to transilluminated powered phlebectomy (TPP/TIPP, TriVex) and stab phlebectomy, are variations of currently accepted surgical techniques for the treatment of varicose veins. In October 2003, the Trivex system, a device for transilluminated powered phlebectomy, was approved by the FDA. A variety of case series describe initial experience with transilluminated powered phlebectomy. In general, these studies demonstrate...
Endovenous Laser Ablation. In 2002, the Diomed 810 nm surgical laser and EVLT (endovenous laser therapy) procedure kit received FDA clearance for use in the endovenous coagulation of the greater saphenous vein of the thigh in patients with superficial vein reflux. There is little clinical evidence in the form of randomized prospective clinical trials to support endovenous laser ablation of the greater saphenous vein (ELAS, EVLT) or transcutaneous laser ablation of small diameter veins. Available studies are small with short-term follow-up. However, available studies support the safety and efficacy of ELAS and EVLT in patients with documented symptomatic saphenofemoral reflux.

Endovenous Laser Ablation. In 2002, the Diomed 810 nm surgical laser and EVLT (endovenous laser therapy) procedure kit received FDA clearance for use in the endovenous coagulation of the greater saphenous vein of the thigh in patients with superficial vein reflux. There is little clinical evidence in the form of randomized prospective clinical trials to support endovenous laser ablation of the greater saphenous vein (ELAS, EVLT) or transcutaneous laser ablation of small diameter veins. Available studies are small with short-term follow-up. However, available studies support the safety and efficacy of ELAS and EVLT in patients with documented symptomatic saphenofemoral reflux.

Endovenous Laser Ablation. In 2002, the Diomed 810 nm surgical laser and EVLT (endovenous laser therapy) procedure kit received FDA clearance for use in the endovenous coagulation of the greater saphenous vein of the thigh in patients with superficial vein reflux. There is little clinical evidence in the form of randomized prospective clinical trials to support endovenous laser ablation of the greater saphenous vein (ELAS, EVLT) or transcutaneous laser ablation of small diameter veins. Available studies are small with short-term follow-up. However, available studies support the safety and efficacy of ELAS and EVLT in patients with documented symptomatic saphenofemoral reflux.

Endovenous Laser Ablation. In 2002, the Diomed 810 nm surgical laser and EVLT (endovenous laser therapy) procedure kit received FDA clearance for use in the endovenous coagulation of the greater saphenous vein of the thigh in patients with superficial vein reflux. There is little clinical evidence in the form of randomized prospective clinical trials to support endovenous laser ablation of the greater saphenous vein (ELAS, EVLT) or transcutaneous laser ablation of small diameter veins. Available studies are small with short-term follow-up. However, available studies support the safety and efficacy of ELAS and EVLT in patients with documented symptomatic saphenofemoral reflux.
Mechanochemical Endovenous Ablation (MOCA). Very few peer-reviewed studies of have been published that address MOCA. Studies that have been published address the safety and efficacy of the ClariVein® system. One study (Elias and Raines, 2012), reported an industry-sponsored safety and efficacy study of the ClariVein® system. Thirty greater saphenous veins in 29 patients were treated with the device. Greater saphenous veins with diameters greater than 12 mm were excluded. 77% of veins were CEAP class 2 with 7% in class 3 (varicose veins and edema) and 16% in class 4a (varicose veins with skin changes). At 6-month follow-up 1 vein had recanalized, for a primary closure rate of 96.7%. No pain during the procedure or adverse events were reported. There is insufficient evidence to permit conclusions regarding the efficacy and safety of mechanochemical endovenous ablation and further controlled studies with longer follow-up are needed.

The National Institute for Health and Clinical Evidence (United Kingdom) issued guidance on endovenous mechanochemical ablation in 2013, concluding that current evidence on the safety and efficacy of endovenous mechanochemical ablation for varicose veins is inadequate in quantity and quality and the procedure should only be used with special arrangements for clinical governance, consent, and audit or research.

According to the National Institute for Health and Care Excellence (NICE), it is recommended that patients with varicose veins and truncal incompetence should provide laser or radiofrequency ablation initially, US-guided foam sclerotherapy (UGFS) if ablation is inappropriate, surgery if US-guided foam sclerotherapy is inappropriate, and compression hosiery if all the stated procedures are inappropriate. Compression hosiery may be used up to seven days with these interventions. Those offered UGFS should be aware of the risks of foam embolization and adverse events such as dry cough, chest tightness, visual disturbance, myocardial infarction, transient ischemic attack (TIA), and seizures.

Sclerotherapy. Two sclerosants (sodium tetradecyl sulfate and sodium sulfate) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of varicose veins of the lower extremity. Published clinical trials support the safety and efficacy of conventional sclerotherapy for lower extremity varicose veins.

The American College of Phlebology (ACP), Society for Vascular Medicine (SVM), Society for Interventional Radiology (SIR), and American Venous Forum (AVG) suggest that indications for endovenous foam sclerotherapy (EFS) include primary treatment and recurrence of small saphenous vein (SSV), great saphenous vein (GSV), and tributary varicose veins; treatment of venous ulcers when conservative measures fall short, and treatment of congenital venous malformations. US guidance is suggested for EFS of varicose veins that are adjacent to named arteries, and when symptoms of deep venous thrombosis (DVT) develop, duplex US is recommended. Moreover, patients should be counseled about major potential adverse events. EFS is contraindicated for those with a prior allergic reaction to foam or liquid sclerosant, and should be avoided in those with a previous foam-induced neurological or symptomatic superficial thrombophlebitis event necessitating treatment. It is necessary to form standards for training and certification for executing endovenous foam sclerotherapy (EFS). Research is required to determine who will benefit most from the procedure as well as to detect those at high risk for adverse events due to EFS, the relative value of EFS to other endovascular techniques, and the influence of EFS on quality of life (QOL).

Furthermore, the German Society of Phlebology guidelines, focusing on polidocanol and sodium tetradecyl sulfate (STS) in liquid or foam recommend that sclerotherapy be executed for reticular varicose veins, incompetent saphenous veins, reticular varicose veins, incompetent perforating veins, tributary varicose veins, telangiectasia, recurrent and residual posttreatment varicose veins, varicose veins of pelvic origin, varicose veins in proximity of leg ulcers, and venous malformations. Liquid sclerotherapy is preferred but foam is also appropriate for C1 disease. Thermal ablation and surgery are well established for incompetent saphenous veins, but foam is also an option. To determine venous incompetence and to guide injection during sclerotherapy, duplex US is recommended before sclerotherapy.

Compressive sclerotherapy has been found to be as effective as surgery in relieving the symptoms associated with varicose veins with few complications. Studies consider sclerotherapy successful based on the absence of Duplex detected flow in the treated segments of the greater saphenous veins, and is associated with a faster postoperative recovery.
Clinical evidence indicates that **sclerotherapy of varicose tributaries alone** is less effective than treatment that includes control of the underlying refluxing veins. However, since recurrence typically arises after 2 to 4 years, isolated sclerotherapy may be medically appropriate for patients in whom long-term control of venous reflux is not a treatment goal. Such patients may include older patients who experience recurrent bleeding form varicose blebs or older patients with recurrent thrombophlebitis in varicose tributaries.

**Sclerotherapy of the greater saphenous vein** raises issues regarding appropriate volume and concentration of the sclerosant and the ability to provide adequate post-procedure compression, since the greater saphenous vein is larger and deeper than telangiectatic dermal veins. Also the use of sclerotherapy, as opposed to the physical removal of the vein with stripping, raises the issue of recurrence due to recanalization.

**Non-compressive sclerotherapy** has not been shown to be effective in producing long-term obliteration of the incompetent veins.

**CODES:**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility for reimbursement is based upon the benefits set forth in the member’s subscriber contract.</td>
<td></td>
</tr>
</tbody>
</table>

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN)

**CPT:**

| 36468 (NMN) | Single or multiple injections of sclerosing solutions, spider veins (telangiectasia), limb or trunk |
| 36470 | Injection of sclerosing solution; single vein |
| 36471 | multiple veins, same leg |
| 36475 | Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated |
| 36476 | second and subsequent veins treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure) |
| 36478 | Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated |
| 36479 | second and subsequent veins treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure) |
| 37765 | Stab phlebectomy of varicose veins, one extremity; 10-20 stab incisions |
| 37766 | more than 20 incisions |
| 37799 | Unlisted procedure, vascular surgery |

**Note:** Used for stab phlebectomy of varicose veins; less than 10 incisions

**Copyright © 2016 American Medical Association, Chicago, IL**

**HCPCS:**

| S2202 | Echosclerotherapy |

**ICD-9:**

| 448.1 (NMN) | Spider nevus (telangiectasis) |
| 454.0 - 454.2, 454.8 | Varicose veins of the lower extremity (code range) |
| 459.81 | Venous insufficiency, unspecified |
REFERENCES:


Guex JJ. Endovenous chemical (and physical) treatments for varices: what's new? Phlebology 2014 May 19;29(1 suppl):45-48 [Epub ahead of print].


Todd KL 3rd, et al; VANISH-2 Investigator Group. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology 2014 Oct;29(9):608-18.


**KEY WORDS:** Ambulatory phlebectomy, ClariVein®, Endolunal radiofrequency ablation, Endovascular embolization, Endovenous laser ablation, Endovenous microwave ablation, Mechanochemical endovenous ablation (MOCA), Microfoam sclerotherapy, Pulse light source, Sclerotherapy, Stab phlebectomy, Steam Vein Sclerosis System, SVSTM, Varithena™, VenaSeal™, VenoSteam™, Transilluminated powered phlebectomy, VNUS.